Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

According to Transparency Market Research, U.S. substance abuse treatment market was value at US$4.42 billion in 2015, and is expected to research US$12.43 Billion by 2024. BioCorRx Inc. (OTC: BICX), Egalet Corporation (NASDAQ: EGLT), Regulus Therapeutics Inc. (NASDAQ: RGLS), DURECT Corporation (NASDAQ: DRRX), Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)

I was concerned that the blue dye would be used to muddy up the water and prevent approval on the next ADCOMM meeting... but I feel greatly relieved that "it" will no longer be an issue, and that Rexista will in fact be approved next time around.

I would prefer if it was partnered before that even if it means accepting a smaller cut.

I think the most important thing right now is for IPCI to secure non dilutive financing and make it clear to everyone that no dilution will be necessary going forward.